106 related articles for article (PubMed ID: 26764285)
1. Copenhagen uPAR prostate cancer (CuPCa) database: protocol and early results.
Lippert S; Berg KD; Høyer-Hansen G; Lund IK; Iversen P; Christensen IJ; Brasso K; Røder MA
Biomark Med; 2016; 10(2):209-16. PubMed ID: 26764285
[TBL] [Abstract][Full Text] [Related]
2. Plasma levels of intact and cleaved urokinase plasminogen activator receptor (uPAR) in men with clinically localised prostate cancer.
Kristensen G; Berg KD; Lippert S; Christensen IJ; Brasso K; Høyer-Hansen G; Røder MA
J Clin Pathol; 2017 Dec; 70(12):1063-1068. PubMed ID: 28607123
[TBL] [Abstract][Full Text] [Related]
3. [Dynamic changes in plasma levels of urokinase type plasminogen activator and urokinase type plasminogen activator receptor in patients with systemic inflammatory response syndrome].
Wu XL; Yu L; Long D; Yang JH; Zhang YC; Geng F
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2011 Aug; 23(8):478-81. PubMed ID: 21878172
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of circulating intact and cleaved forms of urokinase plasminogen activator receptor in inoperable chemotherapy treated cholangiocarcinoma patients.
Grunnet M; Christensen IJ; Lassen U; Jensen LH; Lydolph M; Lund IK; Thurison T; Høyer-Hansen G; Mau-Sørensen M
Clin Biochem; 2014 May; 47(7-8):599-604. PubMed ID: 24530340
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer.
Almasi CE; Brasso K; Iversen P; Pappot H; Høyer-Hansen G; Danø K; Christensen IJ
Prostate; 2011 Jun; 71(8):899-907. PubMed ID: 21456072
[TBL] [Abstract][Full Text] [Related]
6. uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy.
Lund IK; Illemann M; Thurison T; Christensen IJ; Høyer-Hansen G
Curr Drug Targets; 2011 Nov; 12(12):1744-60. PubMed ID: 21707477
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
Zhou H; Wu X; Lu X; Chen G; Ye X; Huang J
Thromb Res; 2009; 123(3):537-42. PubMed ID: 18691743
[TBL] [Abstract][Full Text] [Related]
8. Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum.
Piironen T; Haese A; Huland H; Steuber T; Christensen IJ; Brünner N; Danø K; Høyer-Hansen G; Lilja H
Clin Chem; 2006 May; 52(5):838-44. PubMed ID: 16543389
[TBL] [Abstract][Full Text] [Related]
9. Specific immunoassays for detection of intact and cleaved forms of the urokinase receptor.
Piironen T; Laursen B; Pass J; List K; Gårdsvoll H; Ploug M; Danø K; Høyer-Hansen G
Clin Chem; 2004 Nov; 50(11):2059-68. PubMed ID: 15345662
[TBL] [Abstract][Full Text] [Related]
10. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
[TBL] [Abstract][Full Text] [Related]
11. Urokinase receptor variants in tissue and body fluids.
Høyer-Hansen G; Lund IK
Adv Clin Chem; 2007; 44():65-102. PubMed ID: 17682340
[TBL] [Abstract][Full Text] [Related]
12. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
Shariat SF; Roehrborn CG; McConnell JD; Park S; Alam N; Wheeler TM; Slawin KM
J Clin Oncol; 2007 Feb; 25(4):349-55. PubMed ID: 17264329
[TBL] [Abstract][Full Text] [Related]
13. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
14. Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab.
Tarpgaard LS; Christensen IJ; Høyer-Hansen G; Lund IK; Guren TK; Glimelius B; Sorbye H; Tveit KM; Nielsen HJ; Moreira JM; Pfeiffer P; Brünner N
Int J Cancer; 2015 Nov; 137(10):2470-7. PubMed ID: 25664394
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small cell lung cancer.
Almasi CE; Høyer-Hansen G; Christensen IJ; Pappot H
APMIS; 2009 Oct; 117(10):755-61. PubMed ID: 19775344
[TBL] [Abstract][Full Text] [Related]
16. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients].
Zhou Q; Liang LJ; Peng BG; Zhen YY
Ai Zheng; 2006 Nov; 25(11):1433-8. PubMed ID: 17094916
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients.
Lomholt AF; Christensen IJ; Høyer-Hansen G; Nielsen HJ
Acta Oncol; 2010 Aug; 49(6):805-11. PubMed ID: 20524776
[TBL] [Abstract][Full Text] [Related]
18. Urokinase receptor cleavage correlates with tumor volume in a transgenic mouse model of breast cancer.
Thurison T; Almholt K; Gårdsvoll H; Ploug M; Høyer-Hansen G; Lund IK
Mol Carcinog; 2016 May; 55(5):717-31. PubMed ID: 25809119
[TBL] [Abstract][Full Text] [Related]
19. The concentration of the cleaved suPAR forms in pre- and postoperative plasma samples improves the prediction of survival in colorectal cancer: A nationwide multicenter validation and discovery study.
Rolff HC; Christensen IJ; Svendsen LB; Wilhelmsen M; Lund IK; Thurison T; Høyer-Hansen G; Illemann M; Nielsen HJ;
J Surg Oncol; 2019 Dec; 120(8):1404-1411. PubMed ID: 31646652
[TBL] [Abstract][Full Text] [Related]
20. The liberated domain I of urokinase plasminogen activator receptor--a new tumour marker in small cell lung cancer.
Almasi CE; Drivsholm L; Pappot H; Høyer-Hansen G; Christensen IJ
APMIS; 2013 Mar; 121(3):189-96. PubMed ID: 23030781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]